Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
15. November 2024 11:02 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15. November 2024 11:01 ET
|
Barinthus Biotherapeutics
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
01. Oktober 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Hepatitis: The silent killer
17. Mai 2024 12:37 ET
|
Missouri Department of Health and Senior Services
May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations.
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
12. Oktober 2021 18:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
03. Februar 2020 07:30 ET
|
Enochian Biosciences, Inc.
LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the...
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
10. Dezember 2019 07:00 ET
|
Enochian Biosciences, Inc.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
19. November 2014 07:00 ET
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...